fda announcement semaglutide FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

🚨 FDA Ends Semaglutide Shortage The FDA has officially declared an end to the shortage of semaglutide, the active ingredient in the popular medications Ozempic and Wegovy. This announcement signals a significant

25.80

★★★★☆4.8 (126)

FDA Approves Oral Semaglutide for Obesity Treatment | Michael Weintraub, MD posted on the topic

23.77

★★★★★4.9 (98)

Semaglutide: The Drug of Today and a Steppingstone to Tomorrow

20.79

★★★★★5.0 (157)

As of February 21, 2025, the FDA updated its drug shortage list, marking the semaglutide injection shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and both 503A

24.02

★★★★★4.7 (84)

📢 FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Patients and prescribers may still see intermittent and limited localized supply disruptions as the

20.79

★★★★★4.9 (203)

FDA has approved a new oral form of semaglutide for long-term weight reduction in adults with obesity or overweight. The new oral tablet is also indicated for reducing the risk of major

24.42

★★★★★5.0 (176)

PRESS The US Food and Drug Administration (FDA) has approved our once-weekly high-dose injectable semaglutide (7.2 mg) to reduce excess body weight and maintain more weight loss long-term. Learn more in the

21.14

★★★★★4.8 (132)